Cogent Biosciences

Cogent Biosciences

Cogent Biosciences was founded to develop therapies for genetically defined diseases, building a discovery organization in Boulder and headquarters in Waltham. Andrew Robbins serves as CEO and President; the board includes Fairmount Funds founding partner as a director (firm website). The company's strategy centers on small-molecule precision therapies that address the root cause of disease, not just symptoms. It targets areas where the genetic driver is well-understood and where current drugs have safety or efficacy shortcomings. Cogent operates a wholly-owned discovery engine in Boulder, with development and regulatory teams spread across Waltham, Rockville, and New York. No disclosed clinical-stage pipeline or commercial products as of early 2025. Cogent maintains two US offices—Waltham, MA and Boulder, CO—and lists a Scientific Advisory Board including oncology and genomics specialists from NYU Langone Health, Massachusetts General Hospital Cancer Center, and Icahn School of Medicine at Mount Sinai. The company's clinical trial and expanded access inquiries are handled via a dedicated email address, and a Medical Information line serves healthcare professionals during business hours. Cogent is structured as a publicly traded corporation, not a family office or fund—its capital comes from equity markets and venture investors, not a single family fortune. Its organizational differentiator is the explicit focus on small-molecule precision therapies for well-defined genetic targets, which sets it apart from broader biotech platforms.